Study Comparing Microneedling Combined With 1% Lactic Acid, Vitamin D3, or Triamcinolone Acetonide for Treating Alopecia Areata

What this Trial Is About

Alopecia areata AA is an autoimmune condition causing non-scarring hair loss in round or oval patches, often affecting the scalp, beard, eyebrows, and eyelashes. This trial studies the effects of combining microneedling with either 1% lactic acid solution, vitamin D3, triamcinolone acetonide, or saline to evaluate hair regrowth in patients with localized patchy AA. The study aims to better understand these treatments potential in promoting hair growth by modulating immune responses and stimulating hair follicles. Participants will be divided into four groups, each receiving microneedling with a different topical agent lactic acid 1%, vitamin D3 solution, triamcinolone acetonide injectable suspension, or normal saline. Microneedling sessions will be performed every two weeks for up to six sessions, using a dermapen device with a needle length of 1.5 to 2 mm. Topical anesthetic cream is applied before treatment, and microneedling continues until pinpoint bleeding occurs. During the study, photographs will be taken before, during, and after treatment to monitor progress. The main outcome measured is hair regrowth improvement assessed by the Severity of Alopecia Tool SALT score and percentage of hair growth over three months. Participants will be evaluated regularly, with attention to treatment response and safety, under the supervision of study staff until study completion in late 2026.

Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata